Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Biomarin Beat Expectations in Q2

TheMotleyFool

0 0

You won't find many people who would complain about BioMarin Pharmaceutical's (NASDAQ: BMRN) performance so far this year. The stock has soared 68% since its March low and is now up more than 40% year to date.

BioMarin announced its second-quarter results after the market closed on Tuesday. And it didn't disappoint. Here are the highlights from BioMarin's Q2 update.

Image source: Getty Images.

Source Fool.com

Like: 0

BMRN

Share